Current Clinical Trials
Protocol Number: HZNP-KRY-405
A Phase 1b, Combined Single-Dose and Multiple-Dose, Multicenter, Randomized, Open-Label Trial to Assess Safety and Tolerability of Two Different Dose Levels of Subcutaneous Pegloticase in Subjects with Uncontrolled Gout Receiving Methotrexate.
Protocol Number: HZNP-KRY-405
A Phase 1b, Combined Single-Dose and Multiple-Dose, Multicenter, Randomized, Open-Label Trial to Assess Safety and Tolerability of Two Different Dose Levels of Subcutaneous Pegloticase in Subjects with Uncontrolled Gout Receiving Methotrexate.
Protocol Number: HZNP-KRY-405
A Phase 1b, Combined Single-Dose and Multiple-Dose, Multicenter, Randomized, Open-Label Trial to Assess Safety and Tolerability of Two Different Dose Levels of Subcutaneous Pegloticase in Subjects with Uncontrolled Gout Receiving Methotrexate.
Protocol Number: HZNP-KRY-405
A Phase 1b, Combined Single-Dose and Multiple-Dose, Multicenter, Randomized, Open-Label Trial to Assess Safety and Tolerability of Two Different Dose Levels of Subcutaneous Pegloticase in Subjects with Uncontrolled Gout Receiving Methotrexate.
Protocol Number: HZNP-KRY-405
A Phase 1b, Combined Single-Dose and Multiple-Dose, Multicenter, Randomized, Open-Label Trial to Assess Safety and Tolerability of Two Different Dose Levels of Subcutaneous Pegloticase in Subjects with Uncontrolled Gout Receiving Methotrexate.
Protocol Number: HZNP-KRY-405
HZNP-KRY-405 – A Phase 1b, Combined Single-Dose and Multiple-Dose, Multicenter, Randomized, Open-Label Trial to Assess Safety and Tolerability of Two Different Dose Levels of Subcutaneous Pegloticase in Subjects with Uncontrolled Gout Receiving Methotrexate.
Protocol Number: HZNP-KRY-405
A Phase 1b, Combined Single-Dose and Multiple-Dose, Multicenter, Randomized, Open-Label Trial to Assess Safety and Tolerability of Two Different Dose Levels of Subcutaneous Pegloticase in Subjects with Uncontrolled Gout Receiving Methotrexate.
Protocol Number: HZNP-KRY-405
A Phase 1b, Combined Single-Dose and Multiple-Dose, Multicenter, Randomized, Open-Label Trial to Assess Safety and Tolerability of Two Different Dose Levels of Subcutaneous Pegloticase in Subjects with Uncontrolled Gout Receiving Methotrexate.
Protocol Number: HZNP-KRY-405
A Phase 1b, Combined Single-Dose and Multiple-Dose, Multicenter, Randomized, Open-Label Trial to Assess Safety and Tolerability of Two Different Dose Levels of Subcutaneous Pegloticase in Subjects with Uncontrolled Gout Receiving Methotrexate.